CFT8634, a Potent & Selective Degrader of BRD9 for the Treatment of SMARCB1-perturbed Cancers
Time: 11:30 am
day: Day Two
Details:
- CFT8634 is an orally bioavailable heterobifunctional degrader that induces ubiquitination and degradation of BRD9 by the proteasome.
- CFT8634 promotes potent and selective BRD9 degradation and dosedependent tumor growth inhibition in cell- and patient-derived preclinical SMARCB1-perturbed xenograft models.
- Degradation of BRD9 by CFT8634 offers a promising and novel approach to address this class of difficult-to-treat diseases.
Laura Poling" alt="Laura Poling" itemprop="image">